Detection of Antiviral Drug-Resistant Variants in Chronic Hepatitis C by Deep Sequencing

  • Shinya MaekawaEmail author
  • Mitsuaki Sato
  • Nobuyuki Enomoto


Due to the recent development of various novel small molecule compounds called direct-acting antiviral (DAA) agents and their dramatic antiviral potency against hepatitis C virus (HCV), more than 90 % of patients can now eradicate HCV with DAA therapy, a drastic improvement over the days of interferon therapy both in terms of efficacy and tolerability. On the other hand, the emergence of resistance-associated variants (RAVs) during DAA-based therapy has become a major problem. Namely, due to their high potency and specificity, there is a risk that patients treated with DAAs might develop resistance to one or more classes of DAA. Because of high cross-resistance among the small number of approved DAAs and the limited number of targets, it is also possible for HCV strains resistant to all current DAAs to emerge. Although it is possible to some extent to predict the emergence of RAVs through screening for the presence of RAVs prior to therapy using direct sequencing or other methods, precise and accurate prediction is still not possible because the presence of RAVs at baseline does not guarantee treatment failure nor does the lack of preexisting RAVs preclude the emergence of resistance through de novo mutation during treatment. In order to determine whether the emergence of RAVs is predictable based on the composition of HCV quasispecies prior to treatment, in this study deep sequencing was used to correlate the presence of RAVs at baseline with the emergence of RAVs during treatment in patients treated with interferon-based DAA triple therapy versus interferon-free DAA therapy.


Hepatitis C virus (HCV) Direct-acting antivirals (DAAs) Resistance-associated variants (RAVs) Deep sequencing Phylogenetic analysis 


  1. 1.
    Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med. 1999;131:174–81.CrossRefPubMedGoogle Scholar
  2. 2.
    Asselah T, Marcellin P. Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. Liver Int. 2012;32 Suppl 1:88–102.CrossRefPubMedGoogle Scholar
  3. 3.
    Suzuki F, Sezaki H, Akuta N, Suzuki Y, Seko Y, Kawamura Y, Hosaka T, et al. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. J Clin Virol. 2012;54:352–4.CrossRefPubMedGoogle Scholar
  4. 4.
    Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Muh U, Welker M, Wincheringer D, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology. 2007;132:1767–77.CrossRefPubMedGoogle Scholar
  5. 5.
    Di Maio VC, Cento V, Mirabelli C, Artese A, Costa G, Alcaro S, Perno CF, et al. Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors. Antimicrob Agents Chemother. 2014;58:2781–97.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Shindo H, Maekawa S, Komase K, Sueki R, Miura M, Kadokura M, Shindo K, et al. Characterization of naturally occurring protease inhibitor-resistance mutations in genotype 1b hepatitis C virus patients. Hepatol Int. 2012;6:482–90.CrossRefPubMedGoogle Scholar
  7. 7.
    Martell M, Esteban JI, Quer J, Genesca J, Weiner A, Esteban R, Guardia J, et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol. 1992;66:3225–9.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Nasu A, Marusawa H, Ueda Y, Nishijima N, Takahashi K, Osaki Y, Yamashita Y, et al. Genetic heterogeneity of hepatitis C virus in association with antiviral therapy determined by ultra-deep sequencing. PLoS One. 2011;6:e24907.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Hayashi N, Okanoue T, Tsubouchi H, Toyota J, Chayama K, Kumada H. Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. J Viral Hepat. 2012;19:e134–42.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol. 2012;56:78–84.CrossRefPubMedGoogle Scholar
  11. 11.
    Sato M, Maekawa S, Komatsu N, Tatsumi A, Miura M, Muraoka M, Suzuki Y, et al. Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus. J Virol. 2015;89:6105–16.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Kumada H, Suzuki Y, Ikeda K, Toyota J, Karino Y, Chayama K, Kawakami Y, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014;59:2083–91.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Fridell RA, Qiu D, Wang C, Valera L, Gao M. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother. 2010;54:3641–50.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media Singapore 2017

Authors and Affiliations

  • Shinya Maekawa
    • 1
    Email author
  • Mitsuaki Sato
    • 1
  • Nobuyuki Enomoto
    • 1
  1. 1.First Department of Internal Medicine, Faculty of MedicineUniversity of YamanashiChuoJapan

Personalised recommendations